©2024 Stanford Medicine
99mTc Sestamibi SPECT/CT vs 18F Fluorocholine PET/CT
Not Recruiting
Trial ID: NCT05891769
Purpose
This study proposes the use of a well-established PET isotope, Fluorine-18 (18F), bound to
Choline, for a prospective single-center, single-arm study for participants with suspected
parathyroid adenoma and negative or equivocal standard of care 99mTc Sestamibi SPECT/CT
Official Title
Evaluation of Patients With Suspected Parathyroid Adenoma and Negative or Equivocal 99mTc Sestamibi SPECT/CT Using 18F Fluorocholine PET/CT
Stanford Investigator(s)
Kip E. Guja, MD PhD
Clinical Instructor, Radiology - Rad/Nuclear Medicine
Eligibility
Inclusion Criteria:
1. Suspected parathyroid adenoma (elevated serum calcium and inappropriately normal or
high levels of parathyroid hormone)
2. Negative or equivocal 99mTc Sestamibi SPECT/CT
3. Able to provide written consent
4. Total bilirubin ≤ 1.5 x upper limit of normal (ULN)
5. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 5 xULN
6. Karnofsky performance status of >50 (or ECOG/WHO equivalent)
7. Women must not be pregnant per the Department of Radiology Policy on Imaging in
Potentially Pregnant and Pregnant Women.
Exclusion Criteria:
1. Less than 18 years old at the time of radiotracer administration
2. Creatinine clearance (calculated using Cockcroft-Gault formula, or measured) < 60
mL/min or serum creatinine >1.5 x ULN
3. QTcF >470 msec on electrocardiogram (ECG) or congenital long QT syndrome
Intervention(s):
drug: 18Fluorocholine
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305